1. Home
  2. IRON vs TXG Comparison

IRON vs TXG Comparison

Compare IRON & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$59.06

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$19.18

Market Cap

2.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRON
TXG
Founded
2017
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.3B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
IRON
TXG
Price
$59.06
$19.18
Analyst Decision
Strong Buy
Hold
Analyst Count
11
14
Target Price
$103.18
$17.18
AVG Volume (30 Days)
520.9K
2.2M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.97
EPS
N/A
N/A
Revenue
N/A
$245,893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$283.52
$7.26
P/E Ratio
N/A
N/A
Revenue Growth
N/A
68.06
52 Week Low
$30.82
$6.78
52 Week High
$99.50
$23.56

Technical Indicators

Market Signals
Indicator
IRON
TXG
Relative Strength Index (RSI) 39.24 48.88
Support Level $57.81 $11.62
Resistance Level $64.00 $20.62
Average True Range (ATR) 2.81 1.21
MACD 0.08 -0.23
Stochastic Oscillator 16.99 46.52

Price Performance

Historical Comparison
IRON
TXG

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Share on Social Networks: